Ping Hau Sau Res Group

RES Group is a private drug-development services company focused on mechanistic Quantitative Systems Pharmacology, physiologically-based pharmacokinetic modeling, and broader model-informed drug development support for biopharma clients. The company positions itself as a pioneer in QSP since 2001 and supports first-in-human dose selection, IND-enabling work, regulatory submissions, and translational modeling across modalities including gene therapies, antibodies, antibody-drug conjugates, and small molecules. Rather than advancing a proprietary therapeutic pipeline, RES works as a specialized scientific partner to biotechnology and pharmaceutical companies. Its website cites more than 300 collaborations, experience across over 100 disease indications and modalities, and multiple FDA-related dose prediction and regulatory support successes.